Debiopharm invests $6M into Immunexpress for sepsis test development

Debiopharm, the Swiss diagnostics and drug conglomerate, committed $6 million in new financing to Immunexpress, a startup focused on developing a late-stage sepsis test. Immunexpress has worked with Debiopharm since June 2012. Its SeptiCyte technology is designed to quantify a number of biomarkers in a patient's immune system to enable quick detection and management of sepsis compared to regular pathogen detection. SeptiCyte converts the data into an objective score that makes everything from earlier diagnosis to assessment of severity both easier and more certain. Immunexpress is based in both Australia and the U.S. Story

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.